Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

LiNanlin,Ph.D, Chief Physician,Clinical Professor1 site in 1 country50 target enrollmentJune 2012

ConditionsBreast Cancer Bevacizumab Neoadjuvant Chemotherapy Molecular Targeted Therapy

Interventionsbevacizumab

Drugsbevacizumab

Overview

Phase: Not Applicable
Intervention: bevacizumab
Conditions: Breast Cancer
Sponsor: LiNanlin,Ph.D, Chief Physician,Clinical Professor
Enrollment: 50
Locations: 1
Primary Endpoint: Objective Response Rate
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.

Registry

clinicaltrials.gov

Start Date

June 2012

End Date

September 2014

Last Updated

13 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

LiNanlin,Ph.D, Chief Physician,Clinical Professor

Responsible Party

Sponsor Investigator

Principal Investigator

LiNanlin,Ph.D, Chief Physician,Clinical Professor

The department of Vascular endocrine surgery

Xijing Hospital

Eligibility Criteria

Inclusion Criteria

•HER2-negative breast cancer patients
•Without surgery
•Plans to neoadjuvant chemotherapy

Exclusion Criteria

•HER2-positive breast cancer patients
•Post-operative patients

Arms & Interventions

bevacizumab combined neoadjuvant chemotherapy

Intervention: bevacizumab

Outcomes

Primary Outcomes

Objective Response Rate

Time Frame: From enrollment to disease progression

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.